Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS® T cells
Emeryville, California, October 17, 2022 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced that the

